|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Available-for-sale securities, at fair value (amortized cost $5,137,549 and $6,516,016, respectively; allowance for credit losses $360 and $1,609, respectively) | ||||||||||||||||||||
| Mortgage servicing rights, at fair value | ||||||||||||||||||||
| Mortgage loans held-for-sale, at fair value | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Due from counterparties | ||||||||||||||||||||
| Derivative assets, at fair value | ||||||||||||||||||||
| Reverse repurchase agreements | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Repurchase agreements | ||||||||||||||||||||
| Revolving credit facilities | ||||||||||||||||||||
| Warehouse lines of credit | ||||||||||||||||||||
| Term notes payable | ||||||||||||||||||||
| Senior notes | ||||||||||||||||||||
| Convertible senior notes | ||||||||||||||||||||
| Derivative liabilities, at fair value | ||||||||||||||||||||
| Due to counterparties | ||||||||||||||||||||
| Dividends payable | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Loss contingency accrual | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Commitments and contingencies (see Note 13) | ||||||||||||||||||||
| Stockholders’ Equity: | ||||||||||||||||||||
| Preferred stock, par value $0.01 per share; 100,000,000 shares authorized and 24,870,817 shares issued and outstanding ($621,770 liquidation preference) | ||||||||||||||||||||
| Common stock, par value $0.01 per share; 175,000,000 shares authorized and 105,133,008 and 104,806,311 shares issued and outstanding, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Cumulative earnings | ||||||||||||||||||||
| Cumulative distributions to stockholders | ||||||||||||||||||||
| Total Stockholders’ Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders’ Equity |
Loading...
